{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Scilex Holding Company"},"Symbol":{"label":"Symbol","value":"SCLXW"},"Address":{"label":"Address","value":"94303, United States"},"Phone":{"label":"Phone","value":"(650) 516-4310"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. ZTlido (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of neuropathic pain associated with post-herpetic neuralgia. We have acquired two FDA approved non-opioid pain products, GLOPERBA and ELYXYB, for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults. Our product candidates include SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA TM), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, SP-103 (lidocaine topical system) 5."},"CompanyUrl":{"label":"Company Url","value":"https://www.scilexholding.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Dmitri V. Lissin","title":"Chief Medical Officer & Senior Vice President"},{"name":"Elaine K. Chan","title":"Executive Director & Head-Medical Affairs"},{"name":"Jaisim Shah","title":"President, Chief Executive Officer & Director"},{"name":"Suketu D. Desai","title":"Chief Technical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}